Aquinnah Pharmaceuticals has unveiled promising preclinical research results for a groundbreaking therapeutic designed to slow or halt the progression of Alzheimer's disease and related disorders. Renowned for their expertise in pharmaceutical approaches targeting stress granule biology—a fundamental aspect of various neurodegenerative conditions—Aquinnah's lead compound focuses on the interaction between tau and stress granules. This compound demonstrated an impressive reduction of approximately 70% in tau pathology within an advanced-stage Alzheimer's animal model, as assessed through three distinct markers of pathological tau that also escalate in patients as their disease advances.
Notably, the Aquinnah compound is envisioned to be administered orally as a pill, a preferred method for patients in comparison to the currently required injections for approved Alzheimer's immunotherapies. Administering the compound once daily in preclinical models proved sufficient to achieve a significant reduction in abnormal tau protein, a pivotal factor contributing to memory loss and cognitive decline in Alzheimer's.
Due to its distinctive mechanism of action, this novel compound also holds potential for combination therapy with recently FDA-approved anti-amyloid drugs. If successful in clinical trials, Aquinnah's treatment could be a game-changer for Alzheimer's patients, offering benefits such as reduced brain damage, restored memory function, enhanced cognitive abilities, and a deceleration of disease progression.
Beyond its application to Alzheimer's, Aquinnah's therapeutic shows promise as a potential treatment for other diseases characterized by tauopathies, including Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), Frontotemporal Lobar Dementia (FTD), and Traumatic Brain Injury (TBI).
Dedicated to pioneering research in neurodegenerative conditions, Aquinnah Pharmaceuticals entered into a collaborative agreement with Roche in 2022 to advance oral small molecules for ALS and other neurodegenerative diseases, focusing on modulating TDP-43 pathology—a hallmark feature in over 95% of ALS patients. Aquinnah has received support from Pfizer, AbbVie, and Takeda, along with additional grant funding from esteemed institutions such as the National Institute of Health, the Alzheimer's Association, The Rainwater Foundation, and the Mass Life Sciences Center.